CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
Bone Joint Res 2014;3:146–9.
Hip Knee
Link to article
Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
S. S. Jameson, P. N. Baker, D. J. Deehan, A. Port, M. R. ReedHip Knee
The National Institute for Health and Clinical Excellence (NICE) has thus far relied on historical data and predominantly industry-sponsored trials to provide evidence for venous thromboembolic (VTE) prophylaxis in joint replacement patients. We argue that the NICE guidelines may be reliant on assumptions that are in need of revision. Following the publication of large scale, independent observational studies showing little difference between low-molecular-weight heparins and aspirin, and recent changes to the guidance provided by other international bodies, should NICE reconsider their recommendations?
Link to article